Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from Brokerages

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $12.75.

Several equities research analysts recently weighed in on the company. Citigroup restated a "neutral" rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Stifel Nicolaus reduced their target price on shares of Pulmonx from $17.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, October 31st. Finally, Wells Fargo & Company decreased their price target on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Wednesday, December 11th.

Pulmonx Trading Down 0.5 %

NASDAQ LUNG traded down $0.03 during trading on Wednesday, hitting $6.10. The company had a trading volume of 455,054 shares, compared to its average volume of 377,523. The company's fifty day moving average is $6.52 and its 200-day moving average is $6.86. The company has a market cap of $240.88 million, a price-to-earnings ratio of -4.15 and a beta of 0.69. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx has a one year low of $5.46 and a one year high of $14.84.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same period in the prior year, the firm earned ($0.39) earnings per share. On average, sell-side analysts predict that Pulmonx will post -1.53 earnings per share for the current year.

Insider Activity

In other Pulmonx news, General Counsel David Aaron Lehman sold 5,497 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.19, for a total transaction of $34,026.43. Following the completion of the sale, the general counsel now directly owns 197,851 shares in the company, valued at $1,224,697.69. The trade was a 2.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,376 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $6.18, for a total transaction of $27,043.68. Following the completion of the transaction, the insider now owns 291,057 shares in the company, valued at $1,798,732.26. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 49,873 shares of company stock valued at $324,070 over the last three months. Insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in shares of Pulmonx by 1.8% in the 3rd quarter. Barclays PLC now owns 94,109 shares of the company's stock worth $780,000 after purchasing an additional 1,679 shares in the last quarter. 272 Capital LP purchased a new stake in Pulmonx in the third quarter worth about $25,000. nVerses Capital LLC bought a new position in shares of Pulmonx in the third quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Pulmonx in the second quarter worth about $37,000. Finally, Victory Capital Management Inc. lifted its position in shares of Pulmonx by 1.0% during the 2nd quarter. Victory Capital Management Inc. now owns 834,301 shares of the company's stock valued at $5,289,000 after buying an additional 8,004 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.